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Objectives: The study aimed to synthesize a mutual
prodrug of norfloxacin and fenbufen with an objective of
obtaining an effective and safer anti-inflammatory drug
with useful antimicrobial actions.
Methods: An amide-based mutual prodrug (NF-FN) was
prepared following a single-step synthesis by condensing
norfloxacin with fenbufen under appropriate laboratory
conditions. Its structure was established on the basis of IR,
NMR, Mass spectral data and elemental analysis. The
prodrug (NF-FN) was evaluated for in-vitro antibacterial
activity against two grampositive (Staphylococcus aureus&
Bacillus subtilis) and two gram negative bacterial strains
(Escherichia coli & Klebsiella pneumonia). The in-vivo anti-
inflammatory activity and ulcerogenicity of the synthe-
sized prodrug were investigated inWistar albino rats at the
doses of 10 and 30 mg/kg body weight, respectively.
Results: The synthesized prodrug (NF-FN) showed very
good activity against S. aureus& E. coliwithMIC-6.25 mg/
mL, and good activity against B. subtilis & K. pneumonia
with MIC-12.5 mg/mL. Its anti-inflammatory activity was
found to be better than that of the parent drug fenbufen. It
was also observed to less severe on gastric mucosa in
comparison to reference drug, fenbufen.Corresponding address: Department of Pharmacy, Oman
dical College, P.O. Box 620, Postal Code 130, Muscat, Oman.
E-mail: shahalamkhan@yahoo.com (S.A. Khan)
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Fenbufen (4-oxo-4-[biphenyl-4-yl] butanoic acid) is an
aroylpropionic acid derivative having potent anti-
inflammatory actions. It is used clinically to treat and
manage various inflammatory conditions. It is available in
the market under the name of Cinopal.1 Fenbufen like other
members of aroylpropionic acid class is good anti-
inflammatory agent but causes gastrointestinal side ef-
fects.1,2 One of the synthetic approaches commonly used to
improve the NSAIDs safety profile involves chemical
modification of the free carboxylic group.3e5 Previously
conducted research studies have clearly indicated that
chemical derivatization of the carboxylate function of some
NSAIDs could result in an increased anti-inflammatory ac-
tivity with reduced ulcerogenic effect.6,7
Norfloxacin belongs to fluoroquinolone class of antimi-
crobial agents. A number of derivatives of norfloxacin have
been synthesized with an attempt to improve its antimicro-
bial activities.8,9 Several prodrugs derived from norfloxacinhis is an open access article under the CC BY-NC-ND license
16/j.jtumed.2016.03.003
NO
HO
N
NH
O
F
O
HO
O
N
O
HO
N
N
O
F
O
O
Fenbufen (FN)Norfloxacin (NF)
NF-FN
Phosphorous Oxychloride
Dry Pyridine
+
Scheme 1: Protocol for synthesis of mutual prodrug (NF-FN).
A. Husain et al.278have also shown improved pharmacological and
pharmacokinetic profile.10,11
Prodrug designing is a concept of retro-metabolic drug
design that considers targeting, metabolism, duration of ac-
tion, biological action, side effect, physico-chemical proper-
ties etc. into the drug design process.12,13 Prodrug designing
so far has been proved to be an exciting and fruitful area of
medicinal chemistry research. Generally, in a prodrug, an
inert or non toxic carrier group or promoiety is used,
whose selection primarily depends on the objectives to be
achieved in prodrug designing. In case of mutual prodrug,
the promoiety may be another drug.14 Prodrugs and
mutual prodrugs may exhibit improved biological,
pharmacokinetic, pharmacodynamic properties with or
without minimum side effects.15
In view of these facts and in continuation of our work on
design, synthesis and biologically evaluation of pro-
drugs,10,11 it was considered worthwhile to synthesize a
mutual prodrug comprising of norfloxacin and fenbufen
i.e., two drugs in one with an aim of obtaining an effective
and safer anti-inflammatory drug with useful broad spec-
trum antimicrobial activity against gram positive and gram-
negative bacteria drug with useful antimicrobial actions
against gram-positive and gram-negative bacteria (broad
spectrum). Such drugs might be useful in the inflammatory
conditions associated with infection. The other advantages
of using the prodrug could be its sustained release, admin-
istration of one drug instead of two and low doses that might
be required to produce the desired pharmacological effect.
Materials and Methods
Synthesis
Melting points were recorded in open capillary tube and
are uncorrected. The IR spectrum of the mutual prodrug was
recorded in KBr pellet using a Win IR FTS135 spectropho-
tometer. 1H NMR spectrum was recorded on Bruker spec-
trospin DPX-300 MHz (Rheinstetten, Germany) with
tetramethylsilane (TMS) as an internal standard in solvent
CDCl3. Mass spectrum was recorded on a Jeol JMS-D 300
(Tokyo, Japan) instrument fitted with a JMS 2000 data
system at 70 eV. Microanalysis of the compound was done
on PerkineElmer model 240 analyzer and the values were
found within 0.4% of the theoretical values. The progress
of the reaction was monitored on silica gel G coated plates by
TLC. Iodine chamber and UV-lamp were used for visuali-
zation of TLC spots. Dry solvents were used throughout the
study. The reaction involved in the synthesis of the mutual
prodrug is given in Scheme 1. The starting material 1,
fenbufen i.e., 4-oxo-4-(biphenyl-4-yl)butanoic acid required
for the study was prepared as per the reported method.3
Synthesis of norfloxacin prodrug (NF-FN)
Fenbufen (508 mg; 2 mmol) (1) and norfloxacin 2 (638 mg;
2 mmol) were dissolved separately in dry pyridine (6 & 8 mL,
respectively). Both the solutions were mixed together under
ice cold conditions followed by dropwise addition of phos-
phorous oxychloride (0.5 mL) maintaining the temperature
0e5 C while stirring on a magnetic stirrer. Initially the re-
action mixture was colorless but slowly developed color asreaction proceeded. The contents were then further stirred
for 3 h. After completion of reaction, the reaction mixture
was decomposed by adding on to the ice cold water (100 mL).
A solid mass separated out, which was filtered, washed with
water, dried and crystallized from methanol:chloroform
mixture (1:1) to furnish TLC pure light reddish brown
crystals of NF-FN.
Yield: 46%, m.p.: 228e229 C. Rf: 0.38 (Toluene:Ethyl
acetate:Formic acid, 5:4:1), IR (KBr/nmax) cm
1: 3281 (e
COOH), 3018 (aryl CeH), 2986 & 2834 (CeH), 1731 (C]O),
1658 (CONH), 1621 (C]O, pyridone), 1468 (CeN) and 1237
(CeF), 1H NMR (CDCl3): (d ppm) 1.60 (t, 3H, eCH2CH3),
4.37 (q, 2H,eCH2CH3), 2.87 & 3.42 (t, each, 2x-CH2e), 3.29
& 3.87 (m, each, 4x-CH2e, piperazine moiety), 6.87 (s, 1H,
proton ortho to fluorine), 7.42e7.63 (m, 5H, AreH of p-
phenyl ring), 7.69 & 8.08 (d, each, A2B2, 4H, p-benzoyl ring),
8.05 (s, 1H, proton meta to fluorine), 8.70 (s, 1H, pyridine
ring), MS: m/z 555 (Mþ), C32H30FN3O5; Calculated C, 69.18;
H, 5.44; N, 7.56; Found C, 68.93; H, 5.32; N, 7.48.
Antibacterial activity
The in-vitro antibacterial activity of the newly synthesized
mutual prodrug of (NF-FN) was determined against 4 bac-
terial strains; 2 gram positive bacteria e Staphylococcus
aureus (MTCC 96) & Bacillus subtilis (MTCC 121), and two
gram negative bacteria e Escherichia coli (MTCC 1652) &
Klebsiella pneumonia (ATCC 13883). The minimum inhibi-
tory concentration (MIC) of the test compound and stan-
dard drug norfloxacin was determined according to the
turbidity method.16
Anti-inflammatory activity
The synthesized mutual prodrug was also investigated for
its anti-inflammatory activity by using carrageenan-induced
paw edema method of Winter et al.17 The animal studies
were approved by the Institutional Animal Ethics
Committee [IAEC] of Jamia Hamdard University, New
Delhi and utmost care was taken to ensure that the animals
were treated in the most humane and acceptable manner.
The experiment was performed on Wistar Albino rats of
Table 1: Antimicrobial activity (MIC) of the synthesized
mutual prodrug (NF-FN).
Compound Antibacterial activity
S. aureus B. subtilis E. coli K. pneumonia
NF-FN 6.25 12.5 6.25 12.5
Norfloxacin 3.12 3.12 3.12 6.25
MIC: minimum inhibitory concentration (mg/mL).
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divided into three groups comprising of six animals in each
group. Group I was kept as control, and received only
0.5% carboxymethyl cellulose (CMC) solution. Groups II
and III were labeled as test group and standard group, and
received NF-FN and fenbufen, respectively, in the dose of
10 mg/kg p.o. 0.1 mL of Carrageenan solution (0.1% in
sterile 0.9% NaCl solution) was injected subcutaneously
into the sub-plantar region of the right hind paw of each
rat, 30 min after the administration of the test compound
(FN-NF) and standard drug (fenbufen). The paw volume was
measured using a digital Plethysmometer (Panlab LE 7500) at
4 h after carrageenan injection. The percentage inhibition of
edema was calculated using the formula:
Anti inflammatory activity % inhibitionð Þ
¼ 1 a x=b yð Þ½   100
where, a ¼ paw edema at 4 h after carrageenan in treated
groups; b ¼ paw edema at 4 h after carrageenan in control
group; x¼ normal paw volume of treated group; y ¼ normal
paw volume of control group.
Ulcerogenic activity
In-vivo acute ulcerogenic activity was done as per the
method of Cioli et al.18 Wistar albino rats (180e200 g) which
were used for anti-inflammatory activity were again used
after washing period for determining acute ulcerogenic ac-
tivity of NF-FN. The rats were divided into three groups
consisting of six animals in each group. Ulcerogenic activity
was evaluated after oral administration of test compound
(NF-FN) or fenbufen at the dose of 30 mg/kg. Control rats
received oral administration of vehicle (suspension of 1%
carboxy methyl cellulose). Food but not water was removed
24 h before administration of the test compound. After the
drug treatment, the rats were fed normal diet for 17 h and
then sacrificed. The stomach was removed and opened along
the greater curvature, washed with distilled water and
cleaned gently by dipping in saline. The gastric mucosa of the
rats was examined by means of a magnifying glass. For each
stomach, the severity of mucosal damage was assessed ac-
cording to the following scoring system: 0.5 e redness; 1.0 e
spot ulcers; 1.5 e hemorrhagic streaks; 2.0 e ulcers >3 but
5; 3.0 e ulcers >5. The mean score of each treated group
minus the mean score of the control group was considered as
severity index of gastric mucosal damage.
Statistical analysis
Data were analyzed with the help of a computer program
SPSS ver 19 and the results are presented as the
mean  standard error (SE). One way analysis of variance
(ANOVA) test was used to analyze the statistical significance
in tested groups for ulcerogenic and anti-inflammatory activ-
ity. A value ofP< 0.01 was considered statistically significant.
Results and discussion
Synthesis
The title prodrug (NF-FN) was synthesized in a single step
as outlined in Scheme 1. Norfloxacin (NF) was condensedwith fenbufen (FN) in dry pyridine in presence of POCl3 at
a temperature 0e5 C. Usual work up of the reaction
mixture followed by crystallization from
methanol:chloroform mixture gave the desired prodrug
(NF-FN) as red colored crystalline compound.
Structure elucidation of NF-FN
The structure ofNF-FNwas established on the basis of IR,
1H NMR, mass spectral data and elemental analysis results.
The IR spectrum of the mutual prodrug showed a peak at
3281 cm1 due to stretching of carboxylic eOH group. The
stretching bands due to CeH of aromatic ring, methyl and
methylene groups of ethyl side chain and piperazine ring were
obtained at 3018, 2986 & 2834 cm1, respectively. The three
characteristic bands at 1731, 1655 and 1625were due to C]O
stretching in ester group, tertiary amide group and pyridine
group, respectively. Bands were also present at 1468 (CeN)
and 1237 (CeF) cm1. The 1H NMR spectrum of the pro-
drug NF-FN showed a triplet and a quartet located at d 1.60
and d 4.37 arising from the methyl and methylene group of
ethyl moiety in norfloxacin. There were two triplets located at
d 2.87 and d 3.42 integrating for the protons of twomethylene
groups. There appeared two multiplets located at d 3.29 and
d 3.87 arising from the protons of four methylene groups of
piperazines moiety. There was located a singlet at d 6.87
arising from the lone proton ortho to fluorine atom. Another
singlet located at d 8.15 could be accounted for another lone
proton meta to fluorine. There was a multiplet centered at
d 7.42 which integrated for three protons of the phenyl ring,
the other two protons of this ring appeared as another
multiplet centered at d 7.63. There appeared two doublets
forming anA2B2 pattern located at 7.69 and 8.08 which could
arise from the p-substituted phenyl ring. The lone proton of
pyridine ring appeared as a singlet located at d 8.70. These
data are satisfactory for the structure assigned to the com-
pound. Themass spectrum ofNF-FN showed amolecular ion
peak at m/z 555, and Mþ þ 1 peak at m/z 556. Other peaks
observed were of good intensity and were consistent with the
structure of prepared compound. The elemental analysis
values were found within 0.4% of the theoretical values.
Antibacterial activity
In-vitro antibacterial activity was carried out against the
bacterial strains gram positive (S. aureus & B. subtilis) and
gram negative (E. coli& K. pneumonia). Minimum inhibitory
concentration was determined and results presented in
Table 1 indicate that the prodrug (NF-FN) showed very good
activity against S. aureus & E. coli with MIC-6.25 mg/mL,
and good activity against B. subtilis & K. pneumonia with
MIC-12.5 mg/mL. Norfloxacin showed MIC value ranging
from 3.12 to 6.25 mg/mL against the tested microbes. In-
Table 2: Anti-inflammatory and ulcerogenic activities of the
mutual prodrug (NF-FN).
Treatment Anti-inflammatory activity
(% Inhibition in rat paw edema)
Ulcerogenic
activity
(Severity
index)
Normal
paw volume
(x)
Paw edema
4 h after
carrageenan
(a)
%
inhibition
[1 (a x/
b  y)]100
of edema
Control 0.68  0.02
(y)
0.99  0.03
(b)
e 0.00
NF-FN 0.72  0.05 0.84  0.03 61.30** 0.6  0.1**
Fenbufen 0.71  0.03 0.85  0.04 54.83** 1.5  0.2
**P < 0.01 compared to the parent drug (fenbufen), and data
were given in mean  SEM and analyzed by ANOVA.
A. Husain et al.280vivo antibacterial activities are required to further ascertain
its usefulness; which are under progress in our laboratory.
Anti-inflammatory activity
The in-vivo anti-inflammatory activity of NF-FN was
evaluated by carrageenan-induced rat paw edema method.17
The compound was tested at 10 mg/kg oral dose and was
compared with the parent drug fenbufen at the same oral
dose. The obtained pharmacological results revealed that
the amide prodrug NF-FN was highly active compound
with 61.30% inhibition of inflammation, and its activity
was better than that of the parent drug fenbufen (54.83%)
at the same dose level (10 mg/kg) (Table 2). This increase
in anti-inflammatory activity could be due to synergistic
actions of the norfloxacin and fenbufen. Also, the amide
linkage between fenbufen and norfloxacin is likely to be
hydrolyzed by several amidases present in intestine, thus, free
anti-inflammatory molecule will be released in intestine
preventing its toxic effects on gastric mucosa.19
Ulcerogenic activity
The title compound was screened for ulcerogenic activity
in Wistar albino rats according to the method of Cioli.18
Ulcerogenic activity was evaluated after oral
administration of test compound (NF-FN) or fenbufen at
the dose of 30 mg/kg. The tested compound showed low
ulcerogenic activity, 0.6, whereas the parent drug showed
high severity index, 1.5 (Table 2). So the mutual prodrug
(NF-FN) exhibited better GI profile as compared to the
parent drug fenbufen which could possibly be due to the
conversion of the free carboxylic group of fenbufen to the
amide linkage thereby reducing the gastric irritation caused
by the direct contact of carboxylic acid with the gastric
lining. The amidases found in intestine would likely to
cleavage the amide linkage of the prodrug and therefore,
the NF-FN would pass through the stomach as intact
molecule. The synthesized prodrug is not completely free
from ulcerogenic effects due to non selective inhibition of
cyclooxygenase enzyme.20
Conclusion
A mutual prodrug (NF-FN) was successfully synthesized
by establishing an amide (eCONHe) linkage betweennorfloxacin (NF) with fenbufen (FN) in a single step. The
prodrug (NF-FN) showed significant in-vitro antibacterial
activity against the tested four bacterial strains, and better
anti-inflammatory activity together with low ulcerogenic
action than that of the parent drug fenbufen. It is expected
that after in-vivo hydrolysis (by amidases and/or other en-
zymes) the mutual prodrug would release norfloxacin and
fenbufen into the system which have established antibacterial
and anti-inflammatory activity, respectively. Hydrolysis
studies are in progress in our laboratory to establish the
suggested hypothesis. These results affirm the importance of
exploring old drugs as safer templates to built new mutual
prodrug candidates.Recommendations
Themutual prodrug exhibited enhanced anti-inflammatory
activity along with the reduced gastric toxicity. More detailed
in-vivo studies focusing on pharmacokinetics of drug are
needed to ascertain its usefulness in inflammatory conditions
associated with bacterial infections.Conflict of interest
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